Boulder Bioscience
Privately held biotechnology company developing small-molecule drug candidates and formulation technologies to treat acute brain injuries, including acute ischemic stroke (AIS) and traumatic brain injury (TBI). The company focuses on lipid-based formulation approaches that enable oral and intravenous delivery of a brain-penetrant API, and conducts IND-enabling and translational preclinical studies to support clinical development.
Industries
N/A
Nr. of Employees
small (1-50)
Boulder Bioscience
4909 Nautilus Ct N Ste 130, Boulder, CO 80301, United States
Patents
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
US-11980604-B2
View DetailsMethods for improved endovascular thrombectomy using 3,3′-diindolylmethane
US-11529331-B2
View Details
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
US-11980604-B2
View DetailsMethods for improved endovascular thrombectomy using 3,3′-diindolylmethane
US-11529331-B2
View DetailsProducts
Oral lipid-based self-micro-emulsifying formulation of a neuroprotective small molecule (field formulation)
Oral SMEDDS formulation designed to increase bioavailability of a brain-penetrant small-molecule API for pre-hospital or field administration in mild TBI/concussion and screened AIS patients; IND-enabled with completed 28-day GLP safety toxicology and PK studies in rats.
Intravenous nanoscale emulsion premix of a neuroprotective small molecule
Intravenous premix formulation that forms a nanoscale emulsion on dilution, intended for administration by emergency professionals and interventional neuro-radiologists (e.g., prior to or during thrombectomy); demonstrated pivotal efficacy in a rodent TBI contusion model.
Oral lipid-based self-micro-emulsifying formulation of a neuroprotective small molecule (field formulation)
Oral SMEDDS formulation designed to increase bioavailability of a brain-penetrant small-molecule API for pre-hospital or field administration in mild TBI/concussion and screened AIS patients; IND-enabled with completed 28-day GLP safety toxicology and PK studies in rats.
Intravenous nanoscale emulsion premix of a neuroprotective small molecule
Intravenous premix formulation that forms a nanoscale emulsion on dilution, intended for administration by emergency professionals and interventional neuro-radiologists (e.g., prior to or during thrombectomy); demonstrated pivotal efficacy in a rodent TBI contusion model.
Expertise Areas
- Formulation and drug delivery for poorly soluble small molecules
- Preclinical translational neuroscience (AIS and TBI)
- Neuroinflammation and innate immune modulation
- IND-enabling development and GLP toxicology
Key Technologies
- Self-micro-emulsifying drug delivery systems (SMEDDS)
- Intravenous nanoemulsion/premix formulations
- Small-molecule brain-penetrant APIs
- GLP toxicology and pharmacokinetic studies
News & Updates
Completed GLP-compliant 28-day safety toxicology and pharmacokinetic study supporting IND-enabling status for the oral formulation.
Completed pivotal efficacy study showing neuroprotection, blood–brain barrier protection, reduced cerebral edema, and improved neurocognitive outcomes for the IV formulation in a rigorous translational rodent model.
Completed GLP-compliant 28-day safety toxicology and pharmacokinetic study supporting IND-enabling status for the oral formulation.
Completed pivotal efficacy study showing neuroprotection, blood–brain barrier protection, reduced cerebral edema, and improved neurocognitive outcomes for the IV formulation in a rigorous translational rodent model.